Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Levothyroxine Is No More For Lannett: Here’s How The Company Aims To Replace It

Executive Summary

How do you solve a problem like levothyroxine? Lannett’s management has been wondering exactly that since its partner opted to sign with Amneal instead of renewing its deal with the Philadelphia-based player. A steady stream of launches combined with the company’s cost-cutting scheme should go some way to plugging the gap, Lannett says.


Related Content

Amended Credit Agreement Aids Lannett As It Commits To The US Generics Space 
Lannett will axe 250 under savings scheme


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts